Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Apr 1;160(4):417-424.
doi: 10.1001/jamadermatol.2024.0001.

Anatomic Subtype Differences in Extramammary Paget Disease: A Meta-Analysis

Affiliations
Meta-Analysis

Anatomic Subtype Differences in Extramammary Paget Disease: A Meta-Analysis

Nour Kibbi et al. JAMA Dermatol. .

Abstract

Importance: Extramammary Paget disease (EMPD) is a rare, highly recurrent cutaneous malignant neoplasm of unclear origin. EMPD arises most commonly on the vulvar and penoscrotal skin. It is not presently known how anatomic subtype of EMPD affects disease presentation and management.

Objective: To compare demographic and tumor characteristics and treatment approaches for different EMPD subtypes. Recommendations for diagnosis and treatment are presented.

Data sources: MEDLINE, Embase, Web of Science Core Collection, and Cochrane Reviews CENTRAL from December 1, 1990, to October 24, 2022.

Study selection: Articles were excluded if they were not in English, reported fewer than 3 patients, did not specify information by anatomic subtype, or contained no case-level data. Metastatic cases on presentation were also excluded.

Data extraction and synthesis: Abstracts of 1295 eligible articles were independently reviewed by 5 coauthors, and 135 articles retained. Reporting was in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines. The analysis was cunducted in August 2019 and updated in November 2022.

Findings: Most vulvar EMPD cases were asymptomatic, and diagnosis was relatively delayed (mean, 25.1 months). Although most vulvar EMPD cases were intraepidermal (1247/1773 [70.3%]), radical surgeries were still performed in almost one-third of cases. Despite this aggressive surgical approach, 481 of 1423 (34%) recurred, commonly confined to the skin and mucosa (177/198 [89.4%]). By contrast, 152 of 1101 penoscrotal EMPD cases (14%) recurred, but more than one-third of these recurrences were regional or associated with distant metastases (54 of 152 [35.5%]). Perianal EMPD cases recurred in one-third of cases (74/218 [33.9%]), with one-third of these recurrences being regional or associated with distant metastasis (20 of 74 [27.0%]). Perianal EMPD also had the highest rate of invasive disease (50% of cases).

Conclusions and relevance: The diagnosis and treatment of EMPD should differ based on anatomic subtypes. Considerations for updated practice may include less morbid treatments for vulvar EMPD, which is primarily epidermal, and close surveillance for local recurrence in vulvar EMPD and metastatic recurrence in perianal EMPD. Recurrences in penoscrotal subtype were less common, and selective surveillance in this subtype may be considered. Limitations of this study include the lack of replication cohorts and the exclusion of studies that did not stratify outcomes by anatomic subtype.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Chandra reported advisory board membership from Bristol Myers Squibb, Regeneron, Novartis, and Pfizer outside the submitted work. Dr Leitao reported personal fees from Medtronic, Intuitive Surgical, Inc. Speaker, personal fees from J&J/Ethicon advisory board, and Immunogenicity outside the submitted work. Dr Ross reported personal fees from Foundation Medicine during the conduct of the study. Dr Rossi reported consulting, advisory, and/or travel fees from Evolve CME, Almirall, Mavig, Merz, DynaMed, Canfield Scientific, Allergan, Evolus, Biofrontera, Quantia MD, Lam Therapeutics, Regeneron, Cutera, Skinfix, L'Oréal, and is founder of DAR companies. ASLMS: a Ward Memorial Research Grant. Skin Cancer Foundation: Research Grant. Regen: research/study funding. LeoPharma: research/study funding. Biofrontera: research study funding. editorial board: Lasers in Surgery and Medicine; CUTIS. Editorial Board: Journal of the American Academy of Dermatology (JAAD); Dermatologic Surgery. board member: ASDS. Committee member and/or chair: AAD; ASDS; ASLMS. No other disclosures were reported.

References

    1. Kibbi N, Owen JL, Worley B, et al. . Evidence-based clinical practice guidelines for extramammary paget disease. JAMA Oncol. 2022;8(4):618-628. doi:10.1001/jamaoncol.2021.7148 - DOI - PubMed
    1. Yao H, Xie M, Fu S, et al. . Survival analysis of patients with invasive extramammary Paget disease: implications of anatomic sites. BMC Cancer. 2018;18(1):403. doi:10.1186/s12885-018-4257-1 - DOI - PMC - PubMed
    1. Aoyagi S, Sato-Matsumura KC, Shimizu H. Staging and assessment of lymph node involvement by 18F-fluorodeoxyglucose-positron emission tomography in invasive extramammary Paget’s disease. Dermatol Surg. 2005;31(5):595-598. - PubMed
    1. Akaike G, Nozaki T, Matsusako M, et al. . Magnetic resonance imaging for extramammary Paget’s disease: radiological and pathological correlations. Skeletal Radiol. 2013;42(3):437-442. doi:10.1007/s00256-012-1540-0 - DOI - PubMed
    1. Anjana JS, Rema P, Suchetha S, Ranjith JS, Rao AB, Preethi TR. Impact of surgery on extramammary Paget’s disease vulva: a case series. Indian J Surg Oncol. 2021;12(3):524-529. doi:10.1007/s13193-021-01366-w - DOI - PMC - PubMed

Publication types